Now in press at @AGA_CGH promising results PCB trial of curcumin-QingDai (CurQD) botanical combo. Shown to be a unique AhR agonist which was effective for active UC pts, half of whom IMM/biologics exprienced. my COI of note. @AmerGastroAssn #nutrition.

RT @Adam_goldman_: New publication!. Our study shows that CADe introduction did not improve surveillance colonoscopy performance in #IBD pa….

Psychologist-led group therapy for IBD often very helpful & supportive. Kudo to the fantastic #Dr. Ellen Joseph from @GIPsychUSA .for leading this very nice 🇺🇲 initiative with .@CrohnsColitisFn. We need this all over the 🌍

Terminated development: Combo aTNF+anti FcRn nipocalimab (basically a non-selective IgG reducing strategy) no better than aTNF alone in RA. Further supporting RA (and IBD?) related Ab are not pathogenic but an epiphenomenon. ?.

RT @TakuKobayashiM1: Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis - Cl….

Unique trial & encorouging results of Vedo-Tofa (VETO) combination after failure of either Vedo or Tofa. 14/24 pts had CS free remission W24. What remains unanswered is whether these results would be superior to simply switching to the other agent.

With caveat of non controlled study & small size (and my COI), still nice to have first RWE signal on efficacy of #CurQD in Crohn, not only UC.

Important prospective large 🇪🇦 cohort study showing baseline healthy MD diet & lifestyle reduces risk of IBD flare during follow up. Will it be the same in 🇺🇲 ? or perhaps even more accentuated d/t worse bacground diet ??.

Very interesting study of Yao (NOD2 associated) syndrome, expanding the scope of IBD adjacent disorders (like CMUSE, but very different). Mostly GI motility manifestations but periodic fevers and joints are more like FMF/TRAP.

A bombshell metaanalysis just landed in @AGA_CGH : Advanced therpies work better in colonic #Crohn vs. Ileal dis 😱.aTNFs/aIL23-aIL12/23 were all more effective in the colon, aIntegrin same efficacy in both(?), and JAKi were ONLY EFFECTIVE IN COLON.

Elegant study on isolated anastomotic ulceration ("pure"i2a) shows they also predict higher recurrence risk (and linked with dysbiosis). Bears to reason, as they are rarely seen in non-IBD anastomoses.

RT @AGA_Gastro: If you read this month's Editor's Essential Reading, "Capsule Endoscopy–Guided Proactive Treat-to-Target Versus Continued S….

Very cool pictorial. To add: Both Risa and Miri have Fc LALA mutation to reduce effector ADCC/CDC potential. In contrast, Gus is wild type Ab (unmutated, hence binds CD64=FcRI), but still given/4w or/8w. Whether wild type will yield ⬆️AE or better efficacy remains to be seen.

We're scratching the surface in exploiting #IUS potential as a dynamic test in GI. Intetedting observation from @elrets.

IUS also for monitoring acute severe UC. Intriguingly, loss of stratification (IUS transmural feature) correlated best with CRP (the transmural biomarker ).

RT @IBD_FloMD: ‼️Anyone interested in organ fibrosis please join us for the Keystone Fibrosis Symposium 2026 ‘Cross Organ Pathology and Pat….

💯.Thank u for sharing ! Really moving to hear. Wish u best of health.

Nice case report from @natekrugliak and @guthealthmd in Toronto, on use of #CurQD for a #Crohn patient who flared after having to stop IFX due to dilated cardiomyopathy. @UofT .My COI of note.

As noted in this paper, we dont give prep to SB capsule. Unwarranted, and turns a pt-friendly procedure into much less so.

RT @ericbenchimol: Welcome to Dr Nir Salomon as our guest at the @SickKidsNews 2025 Division of Gastroenterology, Hepatology and Nutrition….

Interesting angle on AhR avtivation by indole derivatives for maintaining barrier integrity and ameliorating IBD.